CORDIS
EU research results

CORDIS

English EN

Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis

Project information

Grant agreement ID: 861942

Status

Ongoing project

  • Start date

    1 October 2019

  • End date

    31 March 2021

Funded under:

H2020-EU.1.1.

Hosted by:

THE UNIVERSITY OF EDINBURGH

United Kingdom

Project description

English EN

The first oral drug for a common liver disease may be on the horizon

Non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, refers to inflammation and damage of the liver caused by a build-up of fat. If NASH gets worse, it can cause scarring of the liver and cirrhosis. Weight loss is recommended in cases of obesity, but there are no medicines to treat it. Cyclophilins are a family of proteins that includes cyclophilin D. Inhibitors of cyclophilin D have been implicated as potential therapeutics but selective, oral agents have been elusive. CYPNASH has discovered a new family of small molecules that inhibit cyclophilins. With expertise in business, pharmaceuticals, and basic research, the team plans to streamline discovery and testing of a suitable NASH therapeutic.

Host institution

THE UNIVERSITY OF EDINBURGH

Address

Old College, South Bridge
Eh8 9yl Edinburgh

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 150 000

Beneficiaries (1)

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 150 000

Project information

Grant agreement ID: 861942

Status

Ongoing project

  • Start date

    1 October 2019

  • End date

    31 March 2021

Funded under:

H2020-EU.1.1.

Hosted by:

THE UNIVERSITY OF EDINBURGH

United Kingdom